Table 1.
Demographic and disease characteristics of patients at baseline and healthy control group
| Variables | Results | Control group |
|---|---|---|
| Age; median (range) | 63 (48–80) | 58 (43–80) |
| Gender | ||
| Male; n (%) | 14 (54) | 6 (50) |
| Female; n (%) | 12 (46) | 6 (50) |
| Histology | ||
| NSCLC; n (%) | 9 (35) | |
| SCLC; n (%) | 2 (8) | |
| Colorectal; n (%) | 4 (15) | |
| Pancreatic; n (%) | 2 (8) | |
| Sarcoma; n (%) | 2 (8) | |
| Other; n (%) | 7 (27) | |
| Stage | ||
| Metastatic; n (%) | 18 (69) | |
| Non-metastatic; n (%) | 8 (31) | |
| Chemotherapy | ||
| Containing platinum; n (%) | 20 (77) | |
| No platinum; n (%) | 6 (23) | |
| Carboplatin, Etoposid; n (%) | 5 (19) | |
| FOLFIRI; n (%) | 3 (12) | |
| Cisplatin, pemetrexed; n (%) | 3 (12) | |
| Carboplatin, pemetrexed; n (%) | 3 (12) | |
| FOLFIRINOX; n (%) | 2 (8) | |
| FLOT; n (%) | 1 (4) | |
| Cisplatin, 5-FU; n (%) | 1 (4) | |
| Paclitaxel; n (%) | 1 (4) | |
| Cisplatin, gemcitabine; n (%) | 1 (4) | |
| Carboplatin, Gemcitabine; n (%) | 1 (4) | |
| Gemicatibene, paclitaxel; n (%) | 1 (4) | |
| Cisplatin, vinorelbine; n (%) | 1 (4) | |
| Cisplatin, paclitaxel; n (%) | 1 (4) | |
| Doxorubicin, cyclophosphamide; n (%) | 1 (4) | |
| Doxorubicin; n (%) | 1 (4) | |
| Response | ||
| CR; n (%) | 4 (15) | |
| PR; n (%) | 7 (27) | |
| SD; n (%) | 9 (35) | |
| PD; n (%) | 6 (23) | |
| G-CSF | ||
| Yes; n (%) | 16 (62) | |
| No; n (%) | 10 (38) | |
| Radiation | ||
| Yes; n (%) | 8 (31) | |
| No; n (%) | 18 (69) | |
| Infection | ||
| Yes; n (%) | 9 (35) | |
| No; n (%) | 17 (65) | |
NSCLC non-small cell lung cancer, SCLC small cell lung cancer, FOLFIRI folinic acid, fluorouracil, irinotecan, FOLFIRINOX folinic acid, fluorouracil, irinotecan, oxaliplatin, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, G-CSF granulocyte-colony stimulating factor